146 related articles for article (PubMed ID: 16625985)
1. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients.
Holdaas H; Hagen E; Asberg A; Lund K; Hartman A; Vaidyanathan S; Prasad P; He YL; Yeh CM; Bigler H; Rouilly M; Denouel J
Int J Clin Pharmacol Ther; 2006 Apr; 44(4):163-71. PubMed ID: 16625985
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
3. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.
Kivistö KT; Kantola T; Neuvonen PJ
Br J Clin Pharmacol; 1998 Jul; 46(1):49-53. PubMed ID: 9690949
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
5. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC.
Siekmeier R; Lattke P; Mix C; Park JW; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):137-45. PubMed ID: 11509920
[TBL] [Abstract][Full Text] [Related]
6. Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers.
Boralli VB; Coelho EB; Sampaio SA; Marques MP; Lanchote VL
J Clin Pharmacol; 2009 Feb; 49(2):205-11. PubMed ID: 19033449
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.
Sabia H; Prasad P; Smith HT; Stoltz RR; Rothenberg P
J Cardiovasc Pharmacol; 2001 May; 37(5):502-11. PubMed ID: 11336101
[TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
[TBL] [Abstract][Full Text] [Related]
10. Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae.
Tse FL; Dain JG; Kalafsky G
Biopharm Drug Dispos; 1995 Apr; 16(3):211-9. PubMed ID: 7787133
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study).
Ilerigelen B; Uresin Y; San M; Kültürsay H; Güneri S; Serdar OA; Güleç S; Pençedemir H;
Curr Med Res Opin; 2007 May; 23(5):1093-102. PubMed ID: 17519076
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies.
Lanchote VL; Rocha A; de Albuquerque FU; Coelho EB; Bonato PS
J Chromatogr B Biomed Sci Appl; 2001 Dec; 765(1):81-8. PubMed ID: 11817313
[TBL] [Abstract][Full Text] [Related]
14. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test.
Schrama YC; Hené RJ; de Jonge N; Joles JA; Van Rijn HJ; Bär DR; Ververs TF; Van Tol A; Koomans HA
Transplantation; 1998 Nov; 66(9):1175-81. PubMed ID: 9825814
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.
Tse FL; Jaffe JM; Troendle A
J Clin Pharmacol; 1992 Jul; 32(7):630-8. PubMed ID: 1640002
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.
Goldberg R; Roth D
Transplantation; 1996 Dec; 62(11):1559-64. PubMed ID: 8970607
[TBL] [Abstract][Full Text] [Related]
18. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
Reyderman L; Kosoglou T; Cutler DL; Maxwell S; Statkevich P
Curr Med Res Opin; 2005 Aug; 21(8):1171-9. PubMed ID: 16083526
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients.
Ambrosi P; Aillaud MF; Habib G; Kreitmann B; Métras D; Luccioni R; Bouvenot G; Juhan-Vague I
Thromb Haemost; 2000 Jan; 83(1):46-8. PubMed ID: 10669153
[TBL] [Abstract][Full Text] [Related]
20. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
